계명대학교 의학도서관 Repository

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Metadata Downloads
Author(s)
Dong-Wan KimDo-Youn OhSeong Hoon ShinJin Hyoung KangByoung Chul ChoJoo-Seop ChungHyeJin KimKeon Uk ParkJung Hye KwonJi-Youn HanMi-Jung KimYung-Jue Bang
Keimyung Author(s)
Park, Keon Uk
Department
Dept. of Internal Medicine (내과학)
Journal Title
BMC Cancer
Issued Date
2014
Volume
14
Issue
1
Abstract
BACKGROUND: The aim of this study was to examine the efficacy and safety of everolimus in patients with progressive unresectable adenoid cystic carcinoma (ACC).

METHODS: Histologically confirmed ACC patients with documented disease progression within 12 months prior to the study entry were eligible. Everolimus was given at a dose of 10 mg daily until progression or occurrence of unacceptable toxicities. The primary endpoint was a 4-month progression-free survival (PFS).

RESULTS: A total of 34 patients were enrolled. The 4-month PFS probability was 65.5% (95% one-sided confidence interval [CI], 47.7 to infinity). Median PFS duration was 11.2 months (95% CI, 3.6 to 15.8). Complete or partial response was not achieved. Twenty-seven (79.4%, 95% CI, 63.2 to 89.6) patients showed stable disease (SD). Tumor shrinkage within SD criteria was observed in 15 patients (44.1%) and SD lasting 6 months was observed in 13 patients (38.2%). Four patients had disease progression. Among the 18 patients with both pre- and post-treatment (at 8 weeks) FDG-PET scans available, 8 patients (44.4%) showed a partial metabolic response, defined as a ≥25% reduction in maximum standardized uptake values (SUVmax). The most common adverse events were stomatitis, anemia, asthenia, and leukopenia. No unexpected everolimus related toxicities were reported.

CONCLUSIONS: Everolimus showed promising efficacy and good tolerability in progressive unresectable ACC.

TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01152840.
Keimyung Author(s)(Kor)
박건욱
Publisher
School of Medicine
Citation
Dong-Wan Kim et al. (2014). A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer, 14(1), 795–795. doi: 10.1186%2F1471-2407-14-795
Type
Article
ISSN
1471-2407
DOI
10.1186%2F1471-2407-14-795
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35236
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.